591 related articles for article (PubMed ID: 21826717)
1. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
Liu HT; Lin H; Kuo HC
Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
[TBL] [Abstract][Full Text] [Related]
2. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder.
Liu HT; Chancellor MB; Kuo HC
BJU Int; 2009 Jun; 103(12):1668-72. PubMed ID: 19220267
[TBL] [Abstract][Full Text] [Related]
3. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention.
Liu HT; Kuo HC
Neurourol Urodyn; 2009; 28(1):78-81. PubMed ID: 19089891
[TBL] [Abstract][Full Text] [Related]
4. Acupuncture versus solifenacin for treatment of overactive bladder and its correlation with urine nerve growth factor levels: a randomized, placebo-controlled clinical trial.
Aydoğmuş Y; Sunay M; Arslan H; Aydın A; Adiloğlu AK; Şahin H
Urol Int; 2014; 93(4):437-43. PubMed ID: 25033919
[TBL] [Abstract][Full Text] [Related]
5. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
Karram MM; Toglia MR; Serels SR; Andoh M; Fakhoury A; Forero-Schwanhaeuser S
Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
8. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence.
Kuo HC; Liu HT; Chancellor MB
Neurourol Urodyn; 2010 Mar; 29(3):482-7. PubMed ID: 19367641
[TBL] [Abstract][Full Text] [Related]
9. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
10. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment.
Liu HT; Kuo HC
Urology; 2008 Jul; 72(1):104-8; discussion 108. PubMed ID: 18400272
[TBL] [Abstract][Full Text] [Related]
11. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
[TBL] [Abstract][Full Text] [Related]
12. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
Kim SR; Moon YJ; Kim SK; Bai SW
Yonsei Med J; 2015 Jan; 56(1):204-11. PubMed ID: 25510766
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
[TBL] [Abstract][Full Text] [Related]
14. Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy.
Liu HT; Jiang YH; Kuo HC
PLoS One; 2013; 8(10):e76706. PubMed ID: 24098552
[TBL] [Abstract][Full Text] [Related]
15. Redefining response in overactive bladder syndrome.
Payne CK; Kelleher C
BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
[TBL] [Abstract][Full Text] [Related]
16. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
17. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity.
Ronchi P; Gravina GL; Galatioto GP; Costa AM; Martella O; Vicentini C
Neurourol Urodyn; 2009; 28(1):52-7. PubMed ID: 18671288
[TBL] [Abstract][Full Text] [Related]
18. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.
Liu HT; Chancellor MB; Kuo HC
Eur Urol; 2009 Oct; 56(4):700-6. PubMed ID: 18472208
[TBL] [Abstract][Full Text] [Related]
19. Solifenacin succinate for the treatment of symptoms of overactive bladder.
Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.
Millard RJ; Halaska M
Curr Med Res Opin; 2006 Jan; 22(1):41-8. PubMed ID: 16393429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
